Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

Inclusion Criteria: * English-speaking * male or female (sex assigned at birth) * 12-18 y/o with obesity (BMI\>120% of the 95th %ile) * 30-45 y/o with obesity (BMI\>35 kg/m2) Exclusion Criteria: * treated with glucagon-like peptide-1 (GLP-1) agonists (e.g., exenatide, liraglutide, semaglutide, tirzepatide) for weight management in the prior 3 months * currently taking anti-psychotic medications (anti-depressants accepted) * diagnosis of type 2 diabetes * current or lifetime anorexia nervosa or current bulimia nervosa * head injury resulting in loss of consciousness \>30min * neurological disorder (e.g., Parkinson's disease) or history of stroke * any contraindication to receiving a MRI (e.g., orthodontal braces) * psychological/behavioral dysfunction (e.g., autism spectrum disorder) or physical impairment that would interfere with study procedures, as determined by study physician * if female, desiring to become pregnant, or currently pregnant or breastfeeding